Acarix AB

Acarix AB

0.16
SEK
-0.01
(-4.41%)
-0.03EPS
240.41MMarket Cap
Feb 11Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.01
0.02
0.03
0.02
0.02
0.02
0.01
0.01
0.01
0.01
Basic EPS, GAAP
-0.74
-0.52
-1.67
-0.59
-0.83
-0.83
-0.39
-0.28
-0.25
-0.16
-0.07
-0.04
-0.03
Free Cash Flow per Basic Share
-0.84
-0.63
-1.16
-0.86
-0.76
-0.79
-0.34
-0.26
-0.25
-0.17
-0.07
-0.03
-0.03
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.3
0.24
3.06
2.54
1.73
0.99
0.45
0.33
0.17
0.07
0.07
0.03
0.03
Tangible Book Value per Share
0.26
-0.1
2.15
2.04
1.26
0.72
0.35
0.28
0.12
0.05
0.06
0.03
0.03
Basic Weighted Avg Shares
26
24
29
51
51
56
107
184
305
475
921
1,127
1,190
Sales/Revenue/Turnover
- -
- -
- -
1
1
2
2
4
6
6
6
7
10
Operating Margin (%)
- -
- -
- -
-4,818.65
-4,152.64
-2,500.97
-1,909.26
-1,374.89
-1,313.55
-1,242.62
-1,070.19
-652.25
-382.93
Depreciation Expense
- -
- -
- -
1
3
4
3
3
3
3
3
3
3
Net Income, GAAP
-19
-12
-48
-30
-42
-46
-41
-52
-77
-78
-66
-48
-38
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-4,667.08
-4,125.98
-2,501.83
-1,912.26
-1,375.82
-1,322.31
-1,247.22
-1,067.19
-653.32
-387.23
Working Capital
13
3
132
104
64
54
63
84
36
39
66
31
33
LT Debt
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
Total Equity
15
12
156
129
88
77
82
101
52
52
76
38
38
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-90.92
-57.55
-20.94
-38.97
-56.49
-52.28
-56.64
-101.05
-150.11
-103.76
-84.47
-98.54

Capital Structure

SEK

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,187
1,241
1,241
Market Capitalization
316
316
240

Working Capital

SEK

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
37
42
37
Cash, Cash Equivalents & STI
26
29
21
Accounts Receivable, Net
4
5
8
Inventories
6
6
6
Total Current Liabilities
7
4
3
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
109.7%
-5.92%
-49.57%
Free Cash Flow
17.11%
6.75%
-40.8%
Net Income, GAAP
32.44%
6.46%
-27.34%
Sales/Revenue/Turnover
- -
30.68%
18.69%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2
2
1
2
6
2025
2
1
2
2
7
2026
2
2
3
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.02
-0.02
-0.01
-0.07
2025
-0.01
-0.01
-0.01
-0.01
-0.04
2026
-0.01
-0.01
-0.01
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Aamir Mahmood
Full Time Employees
8
Sector
Health technology
Industry
Medical specialties
Address
Regus MalmOe Malmö SN Sweden 215 32
IPO Date
Dec 19, 2016
Website
acarix.com
Business
Acarix AB (publ) (ACARIX.ST) develops and commercializes the CADScor System, a non-invasive, AI-based acoustic diagnostic aid for rapid point-of-care rule-out of significant coronary artery disease in symptomatic patients; the system employs ultra-sensitive phonocardiography to detect turbulent coronary blood flow, generating a patient-specific CAD-score (0-99) in under eight minutes using advanced algorithms that incorporate age, gender, and risk factors; it requires disposable patches for single-patient use and integrates with electronic health records via QR code scanning. Founded in 2009 and headquartered in Malmö, Sweden, the company operates primarily in the U.S. market through its subsidiary Acarix USA Inc., with additional presence in the Nordics, United Kingdom, Germany, MENA region, and select international markets via distributors; it targets cardiology practices, emergency departments, outpatient clinics, Veterans Affairs healthcare, concierge medicine, and wellness providers. In recent developments, Acarix enters 2025 with a favorable U.S. CMS ruling for standalone fixed reimbursement of the CADScor System under APC 5733 in outpatient settings, secures multi-unit system orders from national concierge practices and cardiology groups, achieves first commercial sales in MENA with 17 systems sold in Q3 2025, reports 137% Q3 revenue growth to SEK 2.35 million driven by 95% increase in system deliveries and 80% patch sales growth, expands U.S. reimbursement with three major payors removing experimental labels and a second fixed-rate agreement at USD 300 per test including HealthChoice in Oklahoma, advances the Heart Failure Seismo algorithm accepted for American Heart Association presentation, lists shares on OTCQB (ACIXF), adopts a growth-focused usage-based consignment model boosting U.S. placements by 28% year-to-date, and strengthens leadership with key hires in U.S. sales, finance, and reimbursement.

Company News

  • Acarix AB (publ) (ACIXF) Q2 2026 Earnings Call Prepared Remarks Transcript

  • Acarix AB (publ) (ACIXF) Q1 2026 Earnings Call Prepared Remarks Transcript

  • Acarix AB (publ) (ACIXF) Q3 2025 Earnings Call Prepared Remarks Transcript

  • Acarix AB (publ) publishes Interim Report, April - June 2024